Nuvelo Announces Preclinical Data For NU206 Demonstrating Potent Therapeutic Activity In Oral Mucositis Models

Nuvelo, Inc. (Nasdaq: NUVO) announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 (R-spondin1) in chemotherapy or radiation-induced oral mucositis models. The data were presented in a poster session yesterday at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 17th, 2008